2210373
Project Grant
Overview
Grant Description
Sttr Phase I: Bioengineering Lung Surfactant for the Treatment of Respiratory Disease - The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to develop a synthetic lung surfactant product for the potential treatment of serious respiratory illnesses in neonatal patients.
Bronchopulmonary dysplasia affects 10,000-15,000 pre-term infants per year and has a high mortality rate. Exposure of immature lung tissue to air results in inflammation and damages lungs and airways. Decreasing bronchopulmonary dysplasia is anticipated to reduce the number of days infants spend in the hospital, the need for supplemental oxygen, and other burdens on the healthcare system.
The average length of stay in the neonatal intensive care unit for an infant with bronchopulmonary dysplasia is currently 103 days. This Small Business Technology Transfer (STTR) Phase I project may result in the formulation of synthetic proteins for a bioengineered lung surfactant that contains full-length critical phospholipids and anti-inflammatory agents.
Currently, bioengineered pulmonary surfactants are not as effective as animal-derived pulmonary surfactants for the treatment of illnesses related to bronchopulmonary dysplasia such as neonatal respiratory distress syndrome. The synthesis of full-length, native surfactant proteins has yet to be achieved.
This research seeks to synthesize proteins which may add significant viscoelasticity to the pulmonary surfactant. The protein will be combined with major surfactant phospholipids and anti-inflammatory therapeutics at defined ratios to potentially generate fully-synthetic pulmonary surfactant preparations with anti-inflammatory properties. These surfactant formulations will be screened in vitro and in vivo using a neonatal rat hyperoxia model of bronchopulmonary dysplasia.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Bronchopulmonary dysplasia affects 10,000-15,000 pre-term infants per year and has a high mortality rate. Exposure of immature lung tissue to air results in inflammation and damages lungs and airways. Decreasing bronchopulmonary dysplasia is anticipated to reduce the number of days infants spend in the hospital, the need for supplemental oxygen, and other burdens on the healthcare system.
The average length of stay in the neonatal intensive care unit for an infant with bronchopulmonary dysplasia is currently 103 days. This Small Business Technology Transfer (STTR) Phase I project may result in the formulation of synthetic proteins for a bioengineered lung surfactant that contains full-length critical phospholipids and anti-inflammatory agents.
Currently, bioengineered pulmonary surfactants are not as effective as animal-derived pulmonary surfactants for the treatment of illnesses related to bronchopulmonary dysplasia such as neonatal respiratory distress syndrome. The synthesis of full-length, native surfactant proteins has yet to be achieved.
This research seeks to synthesize proteins which may add significant viscoelasticity to the pulmonary surfactant. The protein will be combined with major surfactant phospholipids and anti-inflammatory therapeutics at defined ratios to potentially generate fully-synthetic pulmonary surfactant preparations with anti-inflammatory properties. These surfactant formulations will be screened in vitro and in vivo using a neonatal rat hyperoxia model of bronchopulmonary dysplasia.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF21563
Grant Program (CFDA)
Awarding Agency
Place of Performance
Denver,
Colorado
80206-2761
United States
Geographic Scope
Single Zip Code
Related Opportunity
21-563
Analysis Notes
Amendment Since initial award the End Date has been extended from 05/31/23 to 10/31/24.
Biosuperior Technology was awarded
Project Grant 2210373
worth $255,987
from in June 2022 with work to be completed primarily in Denver Colorado United States.
The grant
has a duration of 2 years 4 months and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
SBIR Details
Research Type
STTR Phase I
Title
STTR Phase I:Bioengineering lung surfactant for the treatment of respiratory disease
Abstract
The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to develop a synthetic lung surfactant product for the potential treatment of serious respiratory illnesses in neonatal patients.Bronchopulmonary dysplasia affects 10,000-15,000 pre-term infants per year and has a high mortality rate. Exposure of immature lung tissue to air results in inflammation and damages lungs and airways. Decreasingbronchopulmonary dysplasia is anticipated to reduce the number of days infants spend in the hospital, the need for supplemental oxygen, and other burdens on the healthcare system. The average length of stay in the neonatal intensive care unit for an infant with bronchopulmonary dysplasia is currently 103 days.This Small Business Technology Transfer (STTR) Phase I project may result in the formulation of synthetic proteins for a bioengineered lung surfactant that contains full-length critical phospholipids and anti-inflammatory agents. Currently, bioengineered pulmonary surfactants are not as effective as animal-derived pulmonary surfactants for the treatment of illnesses related to bronchopulmonary dysplasia such as neonatal respiratory distress syndrome. The synthesis of full-length, native surfactant proteins has yet to be achieved. This research seeks to synthesize proteins which may add significant viscoelasticity to the pulmonary surfactant. The protein will be combined with major surfactant phospholipids and anti-inflammatory therapeutics at defined ratios to potentially generate fully-synthetic pulmonary surfactant preparations with anti-inflammatory properties. These surfactant formulations will be screened in vitro and in vivo using a neonatal rat hyperoxia model of bronchopulmonary dysplasia.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
PT
Solicitation Number
NSF 21-563
Status
(Complete)
Last Modified 7/8/24
Period of Performance
6/15/22
Start Date
10/31/24
End Date
Funding Split
$256.0K
Federal Obligation
$0.0
Non-Federal Obligation
$256.0K
Total Obligated
Activity Timeline
Transaction History
Modifications to 2210373
Additional Detail
Award ID FAIN
2210373
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
J4KSKN7VBPL7
Awardee CAGE
53P98
Performance District
CO-01
Senators
Michael Bennet
John Hickenlooper
John Hickenlooper
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Research and Related Activities, National Science Foundation (049-0100) | General science and basic research | Grants, subsidies, and contributions (41.0) | $255,987 | 100% |
Modified: 7/8/24